{"nctId":"NCT01783041","briefTitle":"Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants","startDateStruct":{"date":"2013-01"},"conditions":["Prematurity","Neurodevelopmental Disorder","Carnitine Deficiency"],"count":144,"armGroups":[{"label":"5% dextrose","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: 5% Dextrose"]},{"label":"L-carnitine","type":"EXPERIMENTAL","interventionNames":["Drug: L-carnitine"]}],"interventions":[{"name":"L-carnitine","otherNames":["Levocarnitine","Carnitor"]},{"name":"5% Dextrose","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Infants born at equal to or less than 30 weeks gestation and with birth weight \\< 1250 grams\n* Less than 72 hours of age\n* Signed parental consent\n\nExclusion Criteria:\n\n* Critically ill infants with life expectancy less than 72 hours\n* Inability to obtain consent within 72 hours of birth\n* Potentially life-threatening congenital anomalies\n* Known hereditary metabolic disorders\n* Known chromosomal abnormalities\n* Terratogen exposure with symptomatic substance withdrawal\n* Congenital viral infections\n* Microcephaly\n* Grade IV intraventricular hemorrhage or seizures documented within the first 72 hours of life","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Day","maximumAge":"3 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Regain Birthweight in Infants Who Receive L-carnitine Supplementation Compared to Controls","description":"Time (in days) for infants in both arms of the study to regain birthweight - data presented as mean +/- SD.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.12","spread":"3.5"},{"groupId":"OG001","value":"8.4","spread":"3.3"}]}]}]},{"type":"PRIMARY","title":"Neurodevelopment Indices in Infants Who Receive L-carnitine Supplementation Compared to Controls (NNNS)","description":"NICU Network Neurobehavioral Scale (NNNS) was administered to study participants at term equivalent age (38 weeks +/-1 week corrected age). The NNNS is a 128-item standardized assessment to evaluate the neurobehavioral status of healthy and high-risk infants. Summary scores include: Attention (range 2.25-8; higher score better), Arousal (range 2-5; lower score better), Regulation (range 3.31-6.92; higher score better), Handling (range 0-0.88; lower score better), Quality of movement (range 3-6; higher score better), Excitability (range 0-9; lower score better), Lethargy (range 0-12; lower score better), Nonoptimal reflexes (range 0-10; lower score better), Asymmetric reflexes (range 0-6; lower score better), Hypertonicity (range 0-2; lower score better), Hypotonicity (range 0-3; lower score better), and Stress/abstinence scale (range 0-0.22; lower score better).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.66","spread":"1.62"},{"groupId":"OG001","value":"4.29","spread":"1.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.073","spread":"0.074"},{"groupId":"OG001","value":"0.079","spread":"0.064"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"0.63"},{"groupId":"OG001","value":"4.6","spread":"0.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.95","spread":"0.6"},{"groupId":"OG001","value":"3.93","spread":"0.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":"0.77"},{"groupId":"OG001","value":"5.5","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"0.28"},{"groupId":"OG001","value":"0.36","spread":"0.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"0.32"},{"groupId":"OG001","value":"0.14","spread":"0.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.57","spread":"0.87"},{"groupId":"OG001","value":"0.22","spread":"0.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"0.79"},{"groupId":"OG001","value":"0.37","spread":"0.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.95","spread":"2.25"},{"groupId":"OG001","value":"4.2","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"2"},{"groupId":"OG001","value":"2.59","spread":"1.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"3"},{"groupId":"OG001","value":"5.2","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"Brain Volumes in Infants Who Received L-carnitine Supplementation Compared to Controls","description":"Brain MRI findings including brain volumes of the cerebellum, thalamus and basal ganglia were compared in infants who received L-carnitine supplementation compared to controls.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19372","spread":"5806"},{"groupId":"OG001","value":"18189","spread":"3826"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6050","spread":"1139"},{"groupId":"OG001","value":"5832","spread":"897"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8611","spread":"1460"},{"groupId":"OG001","value":"8217","spread":"1192"}]}]}]},{"type":"SECONDARY","title":"Rate of Head Growth in Infants Who Receive L-carnitine Supplementation Compared to Controls","description":"Head circumference was measured at 36 weeks corrected age in both study groups (L-carnitine vs. placebo).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":"1.68"},{"groupId":"OG001","value":"30.4","spread":"1.76"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":72},"commonTop":["Blood culture positive sepsis"]}}}